GlassScriptPhysician profile
Marco C Dotti
NPI 1508916263
$8,839.69
in general payments reported to CMS, 2019-2025
31 companies · $1,981 in 2025
The $1,981 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $252 · 2021: $973 · 2022: $1,308 · 2023: $1,669 · 2024: $1,771 · 2025: $1,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,098 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,097.52 |
| Education | $322.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,154.95 | 2019-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $954.61 | 2019-2024 | Austedo Xr |
| Inspire Medical Systems, INC. | $860.89 | 2022-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $728.08 | 2019-2025 | |
| Biogen, INC. | $632.91 | 2019-2024 | Vumerity, Tysabri |
| Pfizer INC. | $414.42 | 2023-2025 | |
| Tg Therapeutics, INC. | $384.68 | 2022-2025 | |
| Harmony Biosciences LLC | $376.75 | 2020-2025 | Wakix |
| Abbvie INC. | $303.80 | 2023-2025 | Ubrelvy, Qulipta |
| E.R. Squibb & Sons, L.L.C. | $293.60 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $289.46 | 2019-2024 | Kisunla, Amyvid, Reyvow |
| Neurelis, INC. | $271.35 | 2021-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $261.37 | 2024-2025 | Ultomiris |
| Mdd US Operations, LLC | $248.04 | 2019-2025 | |
| Ucb, INC. | $245.04 | 2025 | Rystiggo, Zilbrysq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $241.52 | 2023-2025 | |
| Celgene Corporation | $207.89 | 2019-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $160.41 | 2024-2025 | |
| Sk Life Science, INC. | $125.00 | 2025 | Xcopri |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2023 | Hyqvia |
| Corium, LLC | $105.87 | 2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $105.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $98.33 | 2022 | |
| Amgen INC. | $62.76 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $58.49 | 2021 | |
| Allergan, INC. | $39.76 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $18.87 | 2024 | Lumryz |
| Argenx US, INC. | $18.07 | 2023 | Vyvgart Hytrulo |
| Sandoz INC. | $18.01 | 2024 | |
| Supernus Pharmaceuticals, INC. | $17.29 | 2019 | |
| Neurocrine Biosciences, INC. | $16.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Dotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.